Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) traded up 9.6% on Friday . The company traded as high as $0.57 and last traded at $0.57, 313,358 shares were traded during mid-day trading. A decline of 7% from the average session volume of 336,292 shares. The stock had previously closed at $0.52.
A number of research analysts have recently weighed in on the company. ValuEngine raised Aileron Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Aileron Therapeutics in a research report on Monday, September 30th. Finally, Zacks Investment Research cut shares of Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $4.00.
The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.04 and a current ratio of 6.04. The stock’s 50-day moving average is $0.55 and its 200 day moving average is $0.82. The firm has a market cap of $15.69 million, a P/E ratio of -0.27 and a beta of 2.21.
In other news, SVP Vojo Vukovic bought 75,000 shares of the stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $0.59 per share, for a total transaction of $44,250.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Rickenbach Josef H. Von bought 113,145 shares of the stock in a transaction on Friday, September 13th. The shares were purchased at an average price of $0.98 per share, with a total value of $110,882.10. In the last 90 days, insiders purchased 265,211 shares of company stock valued at $207,650. 6.20% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in Aileron Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 261.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 333,005 shares of the company’s stock after purchasing an additional 240,910 shares during the period. Vanguard Group Inc. owned about 2.24% of Aileron Therapeutics worth $240,000 at the end of the most recent reporting period. 26.00% of the stock is owned by institutional investors.
Aileron Therapeutics Company Profile (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.